page 1 of 8 pid a060087 date april 20 2006 from carol a pamer r ph pharmacist drug use specialist sigal kaplan d b pharm pharmacoepidemiologist division surveillance research and communication support hfd 410 through toni piazza hepp acting director to m dianne murphy md office pediatric therapeutics opt oiasi the commissioner solomon iyasu mph development 960 counter terrorism subject one year post exclusivity marketing adverse event review data for gemcitabine gemzar nda 509 grant january 27 2005 this document contains copyrighted proprietary ims health premier that cannot be shared with non fda staff without permission must obtained safety executive summary consult examines utilization trends in population ages 0 16 years primary focus on patterns before following granting national sales perspective
